A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes [2]

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 12, 2007, Pages 1314-1316

  Gerrits, Charles M ^a   Bhattacharya, Mondira ^a   Manthena, Shivaji ^a   Baran, Robert ^a   Perez, Alfonso ^a   Kupfer, Stuart ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE DURATION; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FOLLOW UP; HEALTH ECONOMICS; HEART PROTECTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; INSULIN TREATMENT; LETTER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS;

EID: 37349100453     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1497     Document Type: Letter

References (3)

1. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16: 1065-1071.
2. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006 59(5): 437-447 [Epub 2005 Oct 13].
3. Koro CE, Fu Q, Dirani RG, Fedder DO. Beneficial effects of thiazolidinediones on myocardial infarction risk in patients with type 2 diabetes. Diabetes 2004b; 53(Suppl 2): A247.